BACKGROUND: Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. However, there is no data about the effect of lowering uric acid level on hypertension, renal function, and proteinuria in patients with glomerular filtration rate (GFR) >60 ml/min. We therefore conducted a prospective study to investigate the benefits of allopurinol treatment in hyperuricemic patients with normal renal function. MATERIALS AND METHODS: Forty-eight hyperuricemic and 21 normouricemic patients were included in the study. Hyperuricemic patients received 300 mg/day allopurinol for three months. All patients' serum creatinine level, 24-h urine protein level, glomerular filtration rate, and blood pressure levels were measured at baseline and after three months of treatment. RESULTS: A total of 59 patients completed the three-month follow-up period of observation. In the allopurinol group, serum uric acid levels, GFR, systolic and diastolic blood pressure, and C-reactive protein (CRP) levels significantly improved (P < 0.05). However, urine protein excretion remained unchanged (P > 0.05). No correlation was observed between changes in GFR and changes in CRP, or blood pressure in the allopurinol group. No significant changes were observed in the control group (P > 0.05). CONCLUSION: We bring indirect evidence that hyperuricemia increases blood pressure, and decreases GFR. Hence, management of hyperuricemia may prevent the progression of renal disease, even in patients with normal renal function, suggesting that early treatment with allopurinol should be an important part of the management of chronic kidney disease (CKD) patients. Long-term follow-up studies are warranted to identify the benefits of uric acid management on renal function and hypertension.
BACKGROUND:Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. However, there is no data about the effect of lowering uric acid level on hypertension, renal function, and proteinuria in patients with glomerular filtration rate (GFR) >60 ml/min. We therefore conducted a prospective study to investigate the benefits of allopurinol treatment in hyperuricemicpatients with normal renal function. MATERIALS AND METHODS: Forty-eight hyperuricemic and 21 normouricemic patients were included in the study. Hyperuricemicpatients received 300 mg/day allopurinol for three months. All patients' serum creatinine level, 24-h urine protein level, glomerular filtration rate, and blood pressure levels were measured at baseline and after three months of treatment. RESULTS: A total of 59 patients completed the three-month follow-up period of observation. In the allopurinol group, serum uric acid levels, GFR, systolic and diastolic blood pressure, and C-reactive protein (CRP) levels significantly improved (P < 0.05). However, urine protein excretion remained unchanged (P > 0.05). No correlation was observed between changes in GFR and changes in CRP, or blood pressure in the allopurinol group. No significant changes were observed in the control group (P > 0.05). CONCLUSION: We bring indirect evidence that hyperuricemia increases blood pressure, and decreases GFR. Hence, management of hyperuricemia may prevent the progression of renal disease, even in patients with normal renal function, suggesting that early treatment with allopurinol should be an important part of the management of chronic kidney disease (CKD) patients. Long-term follow-up studies are warranted to identify the benefits of uric acid management on renal function and hypertension.
Authors: Tae Woo Yoo; Ki Chul Sung; Hun Sub Shin; Byung Jin Kim; Bum Soo Kim; Jin Ho Kang; Man Ho Lee; Jung Ro Park; Hyang Kim; Eun Jung Rhee; Won Young Lee; Sun Woo Kim; Seung Ho Ryu; Dong Geuk Keum Journal: Circ J Date: 2005-08 Impact factor: 2.993
Authors: Laura G Sánchez-Lozada; Edilia Tapia; José Santamaría; Carmen Avila-Casado; Virgilia Soto; Tomás Nepomuceno; Bernardo Rodríguez-Iturbe; Richard J Johnson; Jaime Herrera-Acosta Journal: Kidney Int Date: 2005-01 Impact factor: 10.612
Authors: M Mazzali; J Hughes; Y G Kim; J A Jefferson; D H Kang; K L Gordon; H Y Lan; S Kivlighn; R J Johnson Journal: Hypertension Date: 2001-11 Impact factor: 10.190
Authors: Richard J Johnson; Mark S Segal; Titte Srinivas; Ahsan Ejaz; Wei Mu; Carlos Roncal; Laura G Sánchez-Lozada; Michael Gersch; Bernardo Rodriguez-Iturbe; Duk-Hee Kang; Jaime Herrera Acosta Journal: J Am Soc Nephrol Date: 2005-04-20 Impact factor: 10.121
Authors: Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño Journal: Clin J Am Soc Nephrol Date: 2010-06-10 Impact factor: 8.237
Authors: Richard J Johnson; Eric A Gaucher; Yuri Y Sautin; George N Henderson; Alex J Angerhofer; Steven A Benner Journal: Med Hypotheses Date: 2008-03-10 Impact factor: 1.538
Authors: Miguel A Lanaspa; Laura G Sanchez-Lozada; Yea-Jin Choi; Christina Cicerchi; Mehmet Kanbay; Carlos A Roncal-Jimenez; Takuji Ishimoto; Nanxing Li; George Marek; Murat Duranay; George Schreiner; Bernardo Rodriguez-Iturbe; Takahiko Nakagawa; Duk-Hee Kang; Yuri Y Sautin; Richard J Johnson Journal: J Biol Chem Date: 2012-10-03 Impact factor: 5.157
Authors: Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay Journal: J Sex Med Date: 2013-09-25 Impact factor: 3.802
Authors: Ali Bakan; Alihan Oral; Omer Celal Elcioglu; Mumtaz Takir; Osman Kostek; Abdullah Ozkok; Semih Basci; Abdullah Sumnu; Savas Ozturk; Murat Sipahioglu; Aydın Turkmen; Luminita Voroneanu; Adrian Covic; Mehmet Kanbay Journal: Int Urol Nephrol Date: 2015-03-12 Impact factor: 2.370
Authors: Neeraj Dhaun; Vanessa Melville; Scott Blackwell; Dinesh K Talwar; Neil R Johnston; Jane Goddard; David J Webb Journal: J Am Soc Nephrol Date: 2012-12-14 Impact factor: 10.121